SAT-330 Preclinical Screen of Patient CRPC Tumors Shows Sensitivity to Bromodomain Inhibitors Includes AR-null and Neuroendocrine Disease

Castration-resistant prostate cancer (CRPC) remains a lethal disease despite the introduction of second generation androgen receptor (AR) directed therapies. Resistance to AR directed therapies, such as abiraterone and enzalutamide, emerges through diverse alterations in the AR pathway or transition...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:J Endocr Soc
Main Authors: Risbridger, Gail, Ashikari, Daisaku, Lawrence, Mitchell, Obinata, Daisuke, Wang, Hong, Sandhu, Shahneen, Azad, Arun, Taylor, Renea
Formato: Artigo
Idioma:Inglês
Publicado: Endocrine Society 2019
Assuntos:
Tumor Biology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6551945/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/js.2019-SAT-330
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares